Page 8 - Nasdaq Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint...

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) – Equities researchers at Oppenheimer increased their FY2022 earnings per share estimates for shares of Allogene Therapeutics in a report released on Tuesday, August 9th. Oppenheimer analyst M. Breidenbach now expects that the company will earn ($2.43) per share for the year, up from their previous forecast of […]

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) have earned a consensus recommendation of “Buy” from the fifteen ratings firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12-month price […]

Research analysts at Robert W. Baird started coverage on shares of Allogene Therapeutics (NASDAQ:ALLO – Get Rating) in a research report issued on Thursday, The Fly reports. The brokerage set a “neutral” rating on the stock. Several other equities research analysts also recently issued reports on the company. Raymond James dropped their price objective on […]

Analysts expect Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) to report ($0.61) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Allogene Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.67). Allogene Therapeutics reported earnings per share of ($0.53) in the same quarter […]